See more : Aeon Co., Ltd. (AONNF) Income Statement Analysis – Financial Results
Complete financial analysis of Precipio, Inc. (PRPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precipio, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- The Procter & Gamble Company (PRG.DE) Income Statement Analysis – Financial Results
- Ophir Gold Corp. (KPZIF) Income Statement Analysis – Financial Results
- Shanghai Electric Group Company Limited (SIELF) Income Statement Analysis – Financial Results
- Laxmi Organic Industries Limited (LXCHEM.BO) Income Statement Analysis – Financial Results
- Digital Network SA (DIG.WA) Income Statement Analysis – Financial Results
Precipio, Inc. (PRPO)
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.20M | 9.41M | 8.85M | 6.09M | 3.13M | 2.86M | 1.72M | 1.56M | 1.65M | 27.08M | 27.54M | 31.48M | 31.97M | 20.05M | 22.02M | 23.99M | 23.18M | 23.42M | 25.83M | 33.79M | 33.87M | 37.55M | 38.47M | 25.88M | 23.03M |
| Cost of Revenue | 9.18M | 6.90M | 6.46M | 4.94M | 2.91M | 2.64M | 1.43M | 1.76M | 1.94M | 17.36M | 15.05M | 16.47M | 13.53M | 10.28M | 10.42M | 10.35M | 10.48M | 12.05M | 13.50M | 24.60M | 24.32M | 19.57M | 17.20M | 10.89M | 10.58M |
| Gross Profit | 6.02M | 2.51M | 2.39M | 1.15M | 219.00K | 225.00K | 292.00K | -205.00K | -287.00K | 9.72M | 12.50M | 15.01M | 18.44M | 9.76M | 11.61M | 13.65M | 12.69M | 11.37M | 12.33M | 9.19M | 9.55M | 17.99M | 21.27M | 14.99M | 12.46M |
| Gross Profit Ratio | 39.60% | 26.67% | 27.03% | 18.88% | 7.00% | 7.86% | 16.95% | -13.17% | -17.36% | 35.89% | 45.37% | 47.68% | 57.67% | 48.70% | 52.69% | 56.88% | 54.77% | 48.55% | 47.74% | 27.21% | 28.20% | 47.89% | 55.29% | 57.92% | 54.09% |
| Research & Development | 0.00 | 1.70M | 1.30M | 1.20M | 1.20M | 1.10M | 500.00K | 1.42M | 1.85M | 2.90M | 3.21M | 2.49M | 2.22M | 2.31M | 3.18M | 2.47M | 3.03M | 2.36M | 2.20M | 6.69M | 9.31M | 12.20M | 9.37M | 7.65M | 6.30M |
| General & Administrative | 10.32M | 13.51M | 10.61M | 9.00M | 8.32M | 9.45M | 6.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 8.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.42M | 13.61M | 10.71M | 9.10M | 8.42M | 9.45M | 6.49M | 6.19M | 7.06M | 24.15M | 25.04M | 22.02M | 19.15M | 10.93M | 10.32M | 10.80M | 11.47M | 12.14M | 12.22M | 17.50M | 17.32M | 24.20M | 21.64M | 14.91M | 11.53M |
| Other Expenses | 3.22M | 15.31M | 12.01M | 10.30M | 9.62M | -1.33M | 877.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 10.50M | 4.77M | 0.00 | 0.00 | 1.91M | 1.51M |
| Operating Expenses | 13.64M | 15.31M | 12.01M | 10.30M | 9.62M | 9.45M | 6.49M | 7.61M | 8.91M | 27.04M | 28.26M | 24.51M | 21.37M | 13.24M | 13.50M | 13.26M | 14.50M | 14.50M | 14.84M | 34.68M | 31.40M | 36.40M | 31.01M | 24.47M | 19.34M |
| Cost & Expenses | 22.82M | 22.21M | 18.46M | 15.24M | 12.53M | 12.09M | 7.92M | 9.38M | 10.85M | 44.41M | 43.30M | 40.98M | 34.90M | 23.52M | 23.92M | 23.61M | 24.98M | 26.55M | 28.34M | 59.28M | 55.72M | 55.97M | 48.21M | 35.36M | 29.92M |
| Interest Income | 0.00 | 12.00K | 20.00K | 470.00K | 2.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 74.00K | 270.00K | 216.00K | 0.00 | 0.00 | 160.00K | 626.00K | 2.45M | 2.01M | 0.00 |
| Interest Expense | 18.00K | 12.00K | 20.00K | 470.00K | 473.00K | 0.00 | 2.32M | 0.00 | 0.00 | 665.00K | 642.00K | 888.00K | 958.00K | 4.00K | 15.00K | 74.00K | 0.00 | 11.00K | 1.98M | 2.38M | 315.00K | 62.00K | 58.00K | 1.78M | 0.00 |
| Depreciation & Amortization | 1.52M | 1.52M | 1.44M | 1.36M | 1.35M | 1.27M | 743.00K | 112.00K | 489.00K | 2.25M | 2.75M | 2.28M | 2.10M | 708.00K | 855.00K | 882.00K | 950.00K | 1.95M | 4.28M | 4.01M | 8.75M | 3.99M | 3.68M | 1.91M | 1.51M |
| EBITDA | -4.32M | -10.65M | -7.05M | -8.77M | -8.22M | -7.96M | -5.45M | -1.60M | -8.65M | -10.51M | -12.65M | -5.02M | -830.00K | -2.27M | -1.04M | 600.00K | -981.00K | -973.00K | 1.77M | -6.76M | -7.44M | -18.28M | -6.06M | -7.57M | -5.37M |
| EBITDA Ratio | -28.41% | -119.82% | -92.32% | -109.24% | -205.50% | -111.66% | 353.86% | -523.12% | -513.43% | -80.83% | -58.52% | -22.95% | 15.70% | -16.26% | -8.62% | 8.39% | -1.99% | -5.02% | 10.32% | -12.99% | -21.96% | -29.33% | -15.67% | -32.22% | -23.31% |
| Operating Income | -7.62M | -12.80M | -9.61M | -9.15M | -9.40M | -13.91M | -15.51M | -7.82M | -9.20M | -17.32M | -15.76M | -9.50M | -2.97M | -3.61M | -1.90M | -368.00K | -3.32M | -3.13M | -2.51M | -29.06M | -22.59M | -21.70M | -9.74M | -9.48M | -6.88M |
| Operating Income Ratio | -50.14% | -135.96% | -108.63% | -150.13% | -300.74% | -485.75% | -900.23% | -502.18% | -556.26% | -63.96% | -57.21% | -30.19% | -9.30% | -18.02% | -8.61% | -1.53% | -14.33% | -13.37% | -9.72% | -86.00% | -66.70% | -57.78% | -25.32% | -36.61% | -29.88% |
| Total Other Income/Expenses | 1.77M | 619.00K | 1.10M | -1.45M | -2.32M | -2.06M | -5.18M | -515.00K | -1.22M | 3.90M | -282.00K | 1.32M | -6.77M | 628.00K | 18.00K | 86.00K | 243.00K | 198.00K | -2.45M | -5.26M | -5.82M | -2.98M | 2.36M | 996.00K | -1.20M |
| Income Before Tax | -5.85M | -12.18M | -8.52M | -10.60M | -13.31M | -15.97M | -20.69M | -8.27M | -10.14M | -13.42M | -16.04M | -8.18M | -9.74M | -2.98M | -1.88M | -282.00K | -1.93M | -2.93M | -4.96M | -34.47M | -22.89M | -21.26M | -7.38M | -8.48M | -8.08M |
| Income Before Tax Ratio | -38.51% | -129.39% | -96.25% | -173.97% | -425.74% | -557.72% | -1,201.04% | -531.09% | -613.31% | -49.54% | -58.24% | -25.99% | -30.46% | -14.88% | -8.53% | -1.18% | -8.33% | -12.53% | -19.20% | -102.00% | -67.60% | -56.61% | -19.18% | -32.77% | -35.08% |
| Income Tax Expense | 0.00 | 25.00K | 33.00K | 1.63M | -70.00K | -279.00K | 13.87M | -203.00K | 23.76M | 524.00K | -54.00K | 146.00K | 45.00K | 150.00K | 42.00K | 213.00K | 243.00K | 30.00K | 26.00K | -94.00K | 65.00K | 105.00K | 24.00K | 180.00K | 1.75M |
| Net Income | -5.85M | -12.20M | -8.55M | -12.23M | -13.24M | -15.69M | -20.69M | -7.62M | -32.95M | -13.94M | -15.99M | -8.33M | -9.78M | -3.13M | -1.92M | -495.00K | -2.11M | -3.43M | -14.99M | -34.37M | -22.96M | -21.37M | -7.40M | -8.66M | -9.83M |
| Net Income Ratio | -38.51% | -129.65% | -96.62% | -200.76% | -423.50% | -547.97% | -1,201.04% | -489.15% | -1,993.59% | -51.48% | -58.04% | -26.45% | -30.60% | -15.63% | -8.72% | -2.06% | -9.09% | -14.65% | -58.05% | -101.73% | -67.79% | -56.89% | -19.24% | -33.46% | -42.66% |
| EPS | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.81 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| EPS Diluted | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.80 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| Weighted Avg Shares Out | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
| Weighted Avg Shares Out (Dil) | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time.
Precipio Secures a short-term $500K Credit Facility
Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attack Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attack
Precipio Announces Year end 2023 Shareholder Update Call
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET.
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an...
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Results clearly demonstrate the business's ability to reach breakeven in the near future Results clearly demonstrate the business's ability to reach breakeven in the near future
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market.
Precipio Announces Christina Valauri joins the Board of Directors
Douglas Fisher, MD will step down as Director, and remain as a board observer Douglas Fisher, MD will step down as Director, and remain as a board observer
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) shares thoughts and reflections looking back at 2023, and forward to 2024.
Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2023 Earnings Conference Call November 20, 2023 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in...
Source: https://incomestatements.info
Category: Stock Reports